Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial
Top Cited Papers
- 1 August 2007
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 370 (9587) , 580-589
- https://doi.org/10.1016/s0140-6736(07)61297-5
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialThe Lancet, 2006
- Avian influenza vaccines: what's all the flap?The Lancet, 2006
- How prepared is Europe for pandemic influenza? Analysis of national plansThe Lancet, 2006
- Strategies for mitigating an influenza pandemicNature, 2006
- Mitigation strategies for pandemic influenza in the United StatesProceedings of the National Academy of Sciences, 2006
- Influenza pandemic preparedness: gauging from EU plansThe Lancet, 2006
- Mechanism of age-associated up-regulation in macrophage PGE2 synthesisBrain, Behavior, and Immunity, 2004
- Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccineVirus Research, 2004
- Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic useVirus Research, 2004
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001